

[View this email in your browser](#)



Randomized Trial to Prevent Vascular Events in HIV



Circle visit dates on the
NEW 2020 REPRIEVE
calendars!

This will help to remind your participants
of their upcoming visits!

Don't have any calendars? Email Emma at
ekileel@mgh.harvard.edu to request some
for your participants!



We Need Your Input!

REPRIEVE has been successful thanks to the incredible commitment of our 7500+ participants. In recognition of their continued engagement, *we want to thank participants with a REPRIEVE Keepsake*. These keepsakes would be distributed to sites by the REPRIEVE CCC, in turn, sites would distribute them to participants when a participant reaches a study milestone.

To help the CCC determine what would be most appreciated, [CLICK HERE](#) to

complete this 3 question survey! We will be taking surveys until February 1, 2020.

And thank you to everyone who has already completed this survey we really appreciate it!



Happy New Year from the IMPACTA Barranco CRS Team in Peru!

Thank you for all you do on REPRIEVE! We look forward to continuing to work with all REPRIEVE CRS teams in 2020!



REPRIEVE In the News!

In a recent JAMA commentary Dr. Anthony Fauci, Director of NIAID, highlights the lingering challenge of comorbidities in people with HIV.

*"To effectively solve the global health crisis HIV represents, the comorbidities among persons currently living with HIV must be addressed...successfully addressing the comorbidities will require new research advances...In this regard, a large ongoing clinical study, **REPRIEVE**, is investigating whether statin administration can reduce the incidence of major cardiovascular events in persons with HIV."*

Read the full commentary here:


<https://jamanetwork.com/journals/jama/fullarticle/2757599?resultClick=1>

Check Out the Latest OCSO MOB Newsletter!

The DAIDS Office of Clinical Site Oversight (OCSO) Monitoring Operations Branch (MOB) released the 13th edition of the OCSO MOB Newsletter in December. In case you missed it, the newsletter can be found on the HANC website, [DAIDS Resources and Announcements](#) page under OCSO MOB Resources. Or, a direct link to the newsletter is available by clicking [here](#).

Have you sent us your REPRIEVE team photo?

We would like to feature sites on our website and on future newsletters! Please send a team photo and retention or heart healthy tip to reprieve.news@fstrf.org to be featured!



Save the Date!
Tuesday, January 21st, 2019
1:00 – 2:00 PM ET

For the next Monthly Site Call!

If you missed the November monthly site call, [click here](#) to download slides.

REPRIEVE (A5332): Are you up to date?

For A5332 please use:

Protocol Version 5.0 dated 04/01/2019

MOPS Version 5.0 dated 11/29/2019 (updated!)

A5332 LPC for ACTG Sites Version 5.0 dated 04/11/2019

A5332 LPC for Non-ACTG Sites Version 5.0 dated 04/11/2019

These documents are on the [A5332 PSWP](#)

Mechanistic Substudy of REPRIEVE (A5333s): Are you up to date?

For A5333s please use

Protocol Version 5.0 dated 04/01/2019

MOPS Version 4.0 dated 04/10/2018

A5333s LPC Version 4.0 dated 03/23/2018

These documents are on the [A5333s PSWP](#)

For future reference, all newsletters are available on the [REPRIEVE Website](#).

We welcome ideas and suggestions for future newsletters. Please submit any comments or suggestions to the REPRIEVE News team at reprieve.news@fstrf.org



REPRIEVE Trial Clinical Coordinating Center

Massachusetts General Hospital

55 Fruit Street, 5LON 207

Boston, MA USA 02144

Our mailing address is:

reprieve.news@fstrf.org

Want to change how you receive these emails?

You can [update your preferences](#) or [unsubscribe from this list](#).

This email was sent to <<Email Address>>

[why did I get this?](#) [unsubscribe from this list](#) [update subscription preferences](#)

Massachusetts General Hospital · 5 Longfellow Place · Boston, MA 02214 · USA

